Atom Therapeutics

Pharmaceutical Manufacturing • Gusu District, Jiangsu, China • 1-10 Employees

Company overview

Headquarters	Gusu District, Jiangsu, China
Websites	atombp.com atpmbp.com
NAICS	3254
Founded	2012
Employees	1-10
Socials

Key Contact at Atom Therapeutics

William Shi

Chief Executive Officer

About Atom Therapeutics

Atom Therapeutics is a clinical stage biotechnology company founded in 2012. Atom is developing best-in-class orally delivered small molecule drugs for treatment of inflammatoryand metabolic diseases, such as chronic gout, for which there are no effective treatments. Atom’s lead therapy, ABP-671, for chronic gout, is more potent and significantly less toxic than existing drugs, and is poised to enter global Phase 3 trials in 2022. Another compound, ABP-6016, has demonstrated safety and efficacy in preclinical trials for NASH, which is projected to become the most common cause of liver disease. To learn more about Atom Therapeutics visit our website.

Atom Therapeutics revenue & valuation

Annual revenue	$342,220
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues	$1,100,000
Total funding	No funding

Employees by Management Level

Total employees: 1-10

Seniority

Employees

C-Suite

Employees by Department

Atom Therapeutics has 1 employees across 1 departments.

Departments

Number of employees

Funding Data

Atom Therapeutics has never raised funding before.